Cited 31 times in
Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.